Zobrazeno 1 - 10
of 137
pro vyhledávání: '"JL Poveda Andrés"'
Autor:
M Aguar Carrascosa, Á Solaz García, I Lara Cantón, AA Garcia Robles, A Cruz Sánchez, JL Poveda Andrés, A Pinilla González, Á Sánchez Illana
Publikováno v:
Section 7: Post Congress additions.
Autor:
AA Garcia Robles, MDM Serrano Martin, MJ Párraga, E Guerrero Hurtado, P Polo Montanero, JL Poveda Andrés, M Aguar Carrascosa, A Gimeno Navarro
Publikováno v:
Section 7: Post Congress additions.
Autor:
A Ferrada Gascó, JE Megías Vericat, MJ Company Albir, AA García Robles, C Favieres Puigcerver, O Ballesta López, MJ Fernández Megía, FC Pérez Miralles, JL Poveda Andrés, B Casanova Estruch
Publikováno v:
Clinical pharmacy.
Background Progressive multifocal leukoencephalopathy(PML) is caused by JC virus (JCV) and has severe consequences for the central nervous system. PML is an opportunistic infection, affecting HIV positive patients. There is no curative treatment, and
Autor:
AA García Robles, MJ Company Albir, JE Megías Vericat, A Ferrada Gascó, MJ Fernández Megía, FC Pérez Miralles, C Alcalá Vicente, I Boscá Blasco, JL Poveda Andrés, B Casanova Estruch
Publikováno v:
Clinical pharmacy.
Background Inaccessibility of inflammation compartmentalised to the CNS may underlie the lack of effectiveness of immunomodulatory treatments in progressive multiple sclerosis (PMS), turning its treatment into a challenge for researches. Intrathecal
Autor:
M Martin Cerezuela, A Vazquez Polo, E López Briz, R Luna Reina, C Favieres Puigcerver, MJ Company Albir, H Ribes Artero, A Solana Altabella, A Ferrada Gasco, JL Poveda Andrés
Publikováno v:
Clinical pharmacy.
Background The preparation of total parenteral nutrition (TPN) is subject to a great deal of variability in clinical practice due to the complexity of TPN and the variety of professionals involved. Nutritional support is an important care activity in
Autor:
C Favieres Puigcerver, E López Briz, A Melero Zaera, P Pérez Huertas, MJ Company Albir, AA García Robles, M Martín Cerezuela, R Luna Reina, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 23:A132.1-A132
Background Cytomegalovirus disease is an important cause of morbidity and mortality in haematopoietic stem cell transplantation (HSCT) recipients. Foscarnet, an intravenous drug active against cytomegalovirus, represents an increasingly widespread al
Autor:
M Martín Cerezuela, A Solé Jover, MR Marqués Miñana, A Pastor Coll, J Escrivà Peiró, P Pérez Huertas, MJ Company Albir, E Ansotegui Barrera, JP Reig Mezquida, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 23:A192.1-A192
Background Therapeutic monitoring of everolimus is necessary to determine an optimal dosage regimen in lung transplantation patients to prevent graft rejection due to the narrow therapeutic window. The area under the concentration-time curve (AUC –
Autor:
A García Robles, PG Kostadinova, C Borrell García, A Albert Marí, JE Megías Vericat, MJ Company Albir, R Sanz Martinez, P Pérez Huertas, E López Briz, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 23:A242.2-A243
Background Paclitaxel is commonly associated with infusion reactions (IR) with no clear influence of different paclitaxel formulations. Purpose To analyse the number and severity of IR related to administration of different generic formulations of pa
Autor:
J Ruiz Ramos, MJ Company Albir, C Favieres Puigcerver, P Marrero Álvarez, JE Megias Vericat, S Valero García, E López Briz, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 21:A52.2-A52
Background Sinusoidal obstruction syndrome (SOS) is an important non-haematological toxicity in patients who have received chemotherapy for haematopoietic stem cell transplantation (HSCT). In March 2013, European Medicines Agency refused marketing au
Autor:
A García Robles, V Bosó Ribelles, M Cueto Sola, J Ruiz Ramos, MJ Company Albir, MJ Herrero Cervera, SF Aliño Pellicer, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 21:A138.1-A138
Background Inter-individual differences in drug response are linked, in many cases, to single nucleotide polymorphisms (SNPs) in genes coding for drug-metabolising enzymes and transporters. Docetaxel is active for several tumour types, including brea